Preparation and in vitro/in vivo evaluation of revaprazan hydrochloride nanosuspension

International Journal of Pharmaceutics

Volumn 408, Issue 1-2, 2011, Pages 157-162

  Li, Wei ^a   Yang, Yonggang ^b   Tian, Yongshou ^a   Xu, Xinlan ^a   Chen, Yang ^a   Mu, Liwei ^a   Zhang, Yaqiong ^a   Fang, Liang ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Bioavailability rats; Dissolution; High pressure homogenization; Nanosuspension; Revaprazan hydrochloride

Indexed keywords

REVAPRAZAN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; GASTROINTESTINAL ABSORPTION; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SCANNING ELECTRON MICROSCOPY; THERMAL ANALYSIS; X RAY DIFFRACTION;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; FREEZE DRYING; MALE; MICROSCOPY, ELECTRON, SCANNING; MOLECULAR STRUCTURE; NANOPARTICLES; PARTICLE SIZE; PHASE TRANSITION; POWDERS; PROTON PUMP INHIBITORS; PYRIMIDINONES; RATS; RATS, WISTAR; SOLUBILITY; SURFACE PROPERTIES; TETRAHYDROISOQUINOLINES; X-RAY DIFFRACTION;

EID: 79953239695     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2011.01.059     Document Type: Article

References (28)

1. de Waard, H., Hinrichs, W.L.J., Frijlink, H.W., 2008. A novel bottom-up process to produce drug nanocrystals: controlled crystallization during freeze-drying. J. Control. Release 128, 179-183.
2. Han, K.S., Choi, H.C., Yoo, J.K., Lee, J.W., Lee, M.G., 1997. Determination of a new proton pump inhibitor YH1885, in plasma and urine by high-performance liquid chromatography. J. Chromatogr. B 696, 312-316. (Pubitemid 27387459)
3. Han, K.S., Kim, Y.G., Yoo, J.K., Lee, J.W., Lee, M.G., 1998. Pharmacokinetics of a new reversible proton pump inhibitor. YH1885, after intravenous and oral administrations to rats and dogs: hepatic first-pass effect in rats. Biopharm. Drug Dispos. 19, 493-500.
4. Hecq, J., Deleers, M., Fanara, D., Vranckx, H., Amighi, K., 2005. Preparation and 398 characterization of nanocrystals for solubility and dissolution rate enhancement of 399 nifedipine. Int. J. Pharm. 299, 167-177.
5. Hecq, J., Deleers, M., Fanara, D., Vranckx, H., Boulanger, P., Le, L.S., Amighi, K., 2006. Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base. Eur. J. Pharm. Biopharm. 64, 360-368.
6. Hillery, A.M., Florence, A.T., 1996. The effect of adsorbed poloxamer 188 and 407 surfactants on the intestinal uptake of 60-nm polystyrene particles after oral administration in the rat. Int. J. Pharm. 132, 123-130.
7. +-ATPase. In: The Spring Convention of the Pharmaceutical Society of Korea , Pusan, April 24-25, 1998.
8. Jani, P., Halbert, G.W., Langridge, J., Florence, A.T., 1989. The uptake and translocation of latex nanospheres and microspheres after oral administration to rats. J. Pharm. Pharmacol. 41, 809-812.
9. Jani, P., Halbert, G.W., Langridge, J., Florence, A.T., 1990. Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J. Pharm. Pharmacol. 42, 821-826.
10. Jinno, J., Kamada, N., Miyake, M., Yamada, K., Mukai, T., Odomi, M., Toguchi, H., Liversidge, G.G., Higaki, K., Kimura, T., 2006. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J. Control. Release 111, 56-64. (Pubitemid 43289995)
11. Jung, T., Kamm, W., Breitenbach, A., Kaiserling, E., Xiao, J.X., Kissel, T., 2000. Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? Eur. J. Pharm. Biopharm. 50, 147-160.
12. Kim, M.S., Jin, S.J., Kim, J.S., Park, H.J., Song, H.S., Neubert, R.H., Hwang, S.J., 2008. Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process. Eur. J. Pharm. Biopharm. 69, 454-465.
13. Li, H., Chung, S.J., Kim, D.C., Kim, H.S., Lee, J.W., Shim, C.K., 2001. The transport of a reversible proton pump antagonist 5,6-dimethyl-2-(4- fluorophenylamino)- 4-(1-methyl-1,2,3,4-tetrahydroisoquinoline-2-yl) pyrimidine hydrochloride (yh1885), across caco-2 cell monolayers. Drug Metab. Dispos. 29, 54-59.
14. Liversidge, G.G., Conzentino, P., 1995. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int. J. Pharm. 125, 309-313.
15. Loftsson, T., Brewster, M.E., Mässon, M., 2004. Role of cyclodextrins in improving oral drug delivery. Am. J. Drug. Deliv. 2, 261-275.
16. Loftsson, T., Brewster, M.E., 1996. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J. Pharm. Sci. 85, 1017-1025.
17. Makhlof, A., Miyazaki, Y., Tozuka, Y., Takeuchi, H., 2008. Cyclodextrins as stabilizers for the preparation of drug nanocrystals by the emulsion solvent diffusion method. Int. J. Pharm. 357, 280-285.
18. Mauludin, R., Müller, R.H., Keck, C.M., 2009. Kinetic solubility and dissolution velocity of rutin nanocrystals. Eur. J. Pharm. Sci. 36, 502-519.
19. Mosharraf, M., Nyström, C., 1995. The effect of particle size and shape on the surface specific dissolution rate of microsized practically insoluble drugs. Int. J. Pharm. 122, 35-47.
20. Müller, R.H., Akkar, A., 2004. Drug nanocrystals of poorly soluble drugs. Encyclop. Nanosci. Nanotechnol. 2, 627-638.
21. Müller, R.H., Bohn, B.H.L., 1998. Nanosuspensions. In: Müller, R.H., Bohn, B.H.L., Benita, S. (Eds.), Emulsions and Nanosuspensions for the Formulation of Poorly Soluble Drugs. Medpharm, Stuttgart.
22. Noyes, A.A., Whitney, W.R., 1897. The rate of solution of solid substances in their own solutions. J. Am. Chem. Soc. 19, 930-934.
23. Park, Y.J., Hyun, C.K., 2008. Revaprazan-containing solid dispersion and process for the preparation thereof. WO Patent 2008/078922.
24. Sarkari, M., Brown, J., Chen, X., Swinnea, S., Williams, R.O., Johnston, K.P., 2002. Enhanced drug dissolution using evaporative precipitation into aqueous solution. Int. J. Pharm. 243, 17-31, 3rd.
25. Stovall, D.M., Givens, C., Keown, S., Hoover, K.R., Barnes, R., Harris, C., Lozano, J., Nguyen, M., Rodriguez, E., Acree, J.W.E., Abraham, M.H., 2005. Solubility of crystalline nonelectrolyte solutes in organic solvents: mathematical correlation of 4-chloro-3-nitrobenzoic acid and 2-chloro-5-nitrobenzoic acid solubilities with the Abraham solvation parameter model. Phys. Chem. Liq. 43, 351-360.
26. Tao, T., Zhao, Y., Wu, J., Zhou, B., 2009. Preparation and evaluation of itraconazole dihydrochloride for the solubility and dissolution rate enhancement. Int. J. Pharm. 367, 109-114.
27. Wang, Z., Deng, Y., Sun, S., Zhang, X., 2006. Preparation of hydrophobic drugs cyclodextrin complex by lyophilization monophase solution. Drug. Dev. Ind. Pharm. 32, 73-83.
28. Zhong, J., Shen, Z., Yang, Y., Chen, J., 2005. Preparation and characterization of uniform nanosized cephradine by combination of reactive precipitation and liquid anti-solvent precipitation under high gravity environment. Int. J. Pharm. 301, 283-293.